|
Sep 26
|
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
|
|
Aug 19
|
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
|
|
Aug 19
|
COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24…
|
|
Aug 14
|
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
|
|
Feb 20
|
COCP: Cocrystal Pharma provides updates on its clinical programs.
|
|
Jan 4
|
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
|
|
Dec 6
|
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
|
|
Nov 29
|
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
|
|
Nov 27
|
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
|
|
Nov 9
|
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
|